PL376673A1 - Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach - Google Patents

Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach

Info

Publication number
PL376673A1
PL376673A1 PL376673A PL37667304A PL376673A1 PL 376673 A1 PL376673 A1 PL 376673A1 PL 376673 A PL376673 A PL 376673A PL 37667304 A PL37667304 A PL 37667304A PL 376673 A1 PL376673 A1 PL 376673A1
Authority
PL
Poland
Prior art keywords
fusion proteins
improved properties
interferon alpha
alpha muteins
muteins
Prior art date
Application number
PL376673A
Other languages
English (en)
Inventor
Tim Jones
Matthew Baker
Marian Hanlon
Francis Joseph Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL376673A1 publication Critical patent/PL376673A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
PL376673A 2003-02-18 2004-02-18 Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach PL376673A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003647 2003-02-18

Publications (1)

Publication Number Publication Date
PL376673A1 true PL376673A1 (pl) 2006-01-09

Family

ID=32892853

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376673A PL376673A1 (pl) 2003-02-18 2004-02-18 Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach

Country Status (11)

Country Link
US (1) US7456257B2 (pl)
EP (1) EP1594965A2 (pl)
JP (1) JP2007524351A (pl)
KR (1) KR20050107435A (pl)
CN (1) CN1751122A (pl)
AU (1) AU2004213565A1 (pl)
BR (1) BRPI0407533A (pl)
CA (1) CA2516293A1 (pl)
MX (1) MXPA05008704A (pl)
PL (1) PL376673A1 (pl)
WO (1) WO2004074486A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435846T3 (es) * 2005-06-29 2013-12-23 Yeda Research And Development Co. Ltd. Mutantes de Interferón alfa 2 (IFN alfa 2) recombinante
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
KR102037541B1 (ko) 2011-10-28 2019-10-29 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
EA033115B1 (ru) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014183109A1 (en) * 2013-05-10 2014-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for simultaneous detection of hcv antigen/antibody
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
EP3402509A4 (en) 2016-01-14 2019-07-10 Seattle Children's Hospital (DBA Seattle Children's Research Institute) TUMOR SPECIFIC IFNA SECRETION BY CAR T CELLS FOR RESTORING SOLID TUMOR MICRO ENVIRONMENT
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
US20190092818A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
WO2020214690A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
JP2000506865A (ja) * 1996-03-14 2000-06-06 ジ イミューン リスポンス コーポレイション インターフェロンをコードする遺伝子の標的を定めた送達
DK1187852T3 (da) * 1999-05-19 2007-11-26 Merck Patent Gmbh Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
WO2002085941A2 (en) * 2001-03-02 2002-10-31 Merck Patent Gmbh Modified interferon alpha with reduced immunogenicity
PT1512004E (pt) * 2002-06-11 2006-08-31 Merck Patent Gmbh Metodo para mapear e eliminar epitopos para celulas t
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2500626A1 (en) * 2002-10-01 2004-04-15 Xencor, Inc. Interferon variants with improved properties

Also Published As

Publication number Publication date
US7456257B2 (en) 2008-11-25
JP2007524351A (ja) 2007-08-30
CN1751122A (zh) 2006-03-22
WO2004074486A3 (en) 2005-03-31
KR20050107435A (ko) 2005-11-11
EP1594965A2 (en) 2005-11-16
US20070148739A1 (en) 2007-06-28
WO2004074486A2 (en) 2004-09-02
AU2004213565A1 (en) 2004-09-02
BRPI0407533A (pt) 2006-02-14
CA2516293A1 (en) 2004-09-02
MXPA05008704A (es) 2005-10-05

Similar Documents

Publication Publication Date Title
PL376673A1 (pl) Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach
HK1095765A1 (en) Interferon alpha antibodies and their uses
LTC1641823I2 (lt) GLP-1 analogo sulieti baltymai
EP1663278A4 (en) EPO MIMETIC PEPTIDES AND FUSION PROTEINS
PL1673460T3 (pl) Szczepionki rekombinowane i ich zastosowanie
IL166751A0 (en) Modified transferin-antibody fusion proteins
HK1095152A1 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
AU2003239365A8 (en) Recombinant glycosyltransferase fusion proteins
IL176895A0 (en) Purified interleukin-15/fc fusion protein and preparation thereof
HK1158231A1 (en) Uses of interferons with altered spatial structure
ZA200606216B (en) Modified human interferon polypeptides and their uses
IL172269A0 (en) Improved recombinant human interferon-beta-ib polypeptides
PL373052A1 (pl) Polipeptydy fuzyjne glikoprotein płytek IB alfa isposoby ich stosowania
PL363181A1 (pl) Zmodyfikowany interferon alfa o obniżonej immunogeniczności
IL172184A0 (en) Interferon gamma - like protein
PL375218A1 (pl) Zrekombinowane warianty białka
EP1687327A4 (en) NOVEL POLYPEPTIDES ASSOCIATED WITH THERMAL SHOCK PROTEIN 20 AND USES THEREOF
TWI350310B (en) Immunization of fish with plant-expressed recombinant proteins
AU2003272423A8 (en) Centrosome proteins and uses thereof
EP1842857A4 (en) MUTANT PROTEINS OF INTERFERON AND THEIR USE
SI1663110T1 (sl) Uporaba interferonov s spremenjeno prostorsko strukturo
AU2003282159A8 (en) Chimeric recombinant protein and in vitro diagnosis of hiv
EP1541677A4 (en) NEW PROTEINS AND USE THEREOF
EP1577322A4 (en) NEW PROTEINS AND THEIR USE
AU2003232176A8 (en) Protein c variants with altered properties

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)